Tafasitamab clinical trials
Also written MOR00208, XmAb5574, Monjuvi and Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer.
How each study uses tafasitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tafasitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Jul 2020 · MONJUVI · BLA 761163 (FDA, Drugs@FDA)
- European Union
- 26 Aug 2021 · Minjuvi · EMEA/H/C/005436 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
41 studies that test it; most in 2023 (8)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 26
Incyte Corporation (6) · MorphoSys AG (4) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · University of Washington (2) · Beijing InnoCare Pharma Tech Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · Incyte Biosciences Japan GK (1)
Often tested with
Tested in the same studies.
Lenalidomide (17) · Rituximab (9) · Acalabrutinib (5) · Venetoclax (3) · Zanubrutinib (2) · Dexamethasone (2) · Glofitamab (2) · Epcoritamab (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Tafasitamab is the comparator. A study of two new drugs counts under both.
- 1Anti-CD19/CD3 Bispecific Antibody MK-1045 · Merck Sharp & Dohme LLC · next primary completion Mar 2037
Reaching primary completion within a year · 10
Studies that test tafasitamab.
- Dec 2026Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaEarly Phase 1 · Canadian Cancer Trials Group
- Dec 2026Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaPhase 1/2 · James Rubenstein
- Jan 2027Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- Jan 2027Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPhase 1 · OHSU Knight Cancer Institute
- Jan 2027Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyPhase 2 · M.D. Anderson Cancer Center
- Feb 2027Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLPhase 2 · University of Cologne
- Jul 2027Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyPhase 2 · City of Hope Medical Center
- Aug 2027A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLPhase 2 · M.D. Anderson Cancer Center
- Aug 2027Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabPhase 2 · Incyte Corporation
- Sep 2027Study of Acalabrutinib and Tafasitamab in MZL PatientsPhase 2 · International Extranodal Lymphoma Study Group (IELSG)
Studies
Open first, then newest update. How each study uses tafasitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 41
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT07582159Written as Tafasitamab
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06434363Written as Tafasitamab
- Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaRecruitingPhase 2University of WashingtonNCT07731789Written as Tafasitamab
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07126236Written as Epcoritamab, tafasitamab and lenalidomide
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingPhase 1/2Alvaro Alencar, MDNCT06029309Written as Tafasitamab
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT05615636Written as Tafasitamab
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingPhase 1Paolo Caimi, MDNCT07225439Written as Tafasitamab
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingPhase 2Brown UniversityNCT07502872Written as Tafasitamab
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06792825Written as Tafasitamab
- Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaRecruitingPhase 1/2James RubensteinNCT05351593Written as Tafasitamab
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderRecruitingPhase 2Timothy VoorheesNCT05786040Written as Tafasitamab
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06760156Written as Tafasitamab
- Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage LeukemiaRecruitingPhase 1/2University Hospital TuebingenNCT05366218Written as Tafasitamab
- Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabRecruitingPhase 2Incyte CorporationNCT06465433Written as Tafasitamab
- Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingPhase 1OHSU Knight Cancer InstituteNCT05943496Written as Tafasitamab
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingPhase 2University of CologneNCT05583071Written as Tafasitamab
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2Academic and Community Cancer Research UnitedNCT05910801Written as Tafasitamab
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT06521255Written as Tafasitamab
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingPhase 2Beijing InnoCare Pharma Tech Co., Ltd.NCT05552937Written as Tafasitamab and Lenalidomide
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingPhase 3Incyte CorporationNCT05429268Written as Tafasitamab
See all 41 studies that test tafasitamab →
Given beside what is tested · 12 — tafasitamab is usual care or a partner of the new treatment
- Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07938619Written as Tafasitamab
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingPhase 2SWOG Cancer Research NetworkNCT05890352Written as Tafasitamab
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07585747Written as Tafasitamab
- Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationSuspendedPhase 1City of Hope Medical CenterNCT05993611Written as Tafasitamab
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingPhase 1/2University of WashingtonNCT05455697Written as Tafasitamab
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingPhase 1/2CelgeneNCT03930953Written as Tafasitamab
- A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedPhase 1/2Incyte CorporationNCT04809467Written as tafasitamab
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnPhase 1/2Karyopharm Therapeutics IncNCT04607772Written as Tafasitamab
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedPhase 1/2PfizerNCT05626322Written as Tafasitamab
- Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)TerminatedPhase 2Xencor, Inc.NCT05328102Written as Tafasitamab
- Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedPhase 2MorphoSys AGNCT02639910Written as Tafasitamab
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnPhase 1/2CelgeneNCT04882163Written as Tafasitamab
As the comparator · 1 — what is tested is compared with tafasitamab
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
Results posted1
Codes
What other systems call tafasitamab · ClinicalTrials.gg INT000583
- MeSH (NLM) C000613469tafasitamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QQA9MLH692TAFASITAMABConfirmed FDA, NLM, Wikidata
- RxNorm 2387211One source FDA
- Wikidata Q98078915tafasitamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95768TafasitamabOne source FDA
- DrugBank DB15044One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613469 | tafasitamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QQA9MLH692 | TAFASITAMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2387211 | — | One source FDA |
| Wikidata | Q98078915 | tafasitamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95768 | Tafasitamab | One source FDA |
| DrugBank | DB15044 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.